Literature DB >> 16139922

A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.

Agustín Albillos1, Rafael Bañares, Mónica González, María-Vega Catalina, Luis-Miguel Molinero.   

Abstract

BACKGROUND/AIMS: Meta-analysis designed to provide evidence-based guidance on the effect of TIPS and paracentesis on mortality and encephalopathy in cirrhotic patients with refractory ascites.
METHODS: Five randomized trials published between 1989 and 2005 were identified.
RESULTS: The five trials involved 330 patients, and none included patients >76 years, with bilirubin >5-10 mg/dl or creatinine >3 mg/dl. Ascites recurrence was lower in the TIPS arm (RR 0.56; 95% CI 0.47-0.66). TIPS was associated with a greater risk of encephalopathy (RR 1.36; 95% CI 1.1-1.68) and severe encephalopathy (RR 1.72; 95% CI 1.14-2.58). TIPS did not affect mortality, as estimated by the RR (0.93; 95% CI 0.67-1.28, random effect model) and pooled hazard ratio (RR 1.09; 95% CI 0.84-1.88). Analysis of this outcome measure was limited by significant heterogeneity among trials. Liver-related mortality was homogenous and similar in both arms. Results were unaffected by excluding trials of lower quality or with a greater number of alcoholics. Meta-analysis of trials including patients with recidivant ascites revealed a lower mortality in the TIPS arm (RR 0.68; 95% CI 0.49-0.93).
CONCLUSIONS: In patients with refractory ascites, a better control of ascites by TIPS does not translate into improved survival and worsens encephalopathy.

Entities:  

Mesh:

Year:  2005        PMID: 16139922     DOI: 10.1016/j.jhep.2005.06.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

1.  Treatment of refractory ascites.

Authors:  Praveena G Velamati; H Franklin Herlong
Journal:  Curr Treat Options Gastroenterol       Date:  2006

Review 2.  What's new in the treatment of ascites and spontaneous bacterial peritonitis.

Authors:  Andrés Cárdenas; Pere Ginès
Journal:  Curr Gastroenterol Rep       Date:  2008-02

Review 3.  Ascites in Children.

Authors:  Ashish Bavdekar; Nitin Thakur
Journal:  Indian J Pediatr       Date:  2016-06-09       Impact factor: 1.967

4.  New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt.

Authors:  Jennifer Guy; Ma Somsouk; Stephen Shiboski; Robert Kerlan; John M Inadomi; Scott W Biggins
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-26       Impact factor: 11.382

Review 5.  Transjugular intrahepatic portosystemic shunt: An overview.

Authors:  Harjit K Bhogal; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-11-09

6.  Best Use of the Transjugular Intrahepatic Portosystemic Shunt Procedure for the Management of Portal Hypertension.

Authors:  Lisa B VanWagner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

7.  Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.

Authors:  Andrew S Allegretti; Xavier Vela Parada; Guillermo A Ortiz; Joshua Long; Scott Krinsky; Sophia Zhao; Bryan C Fuchs; Mozhdeh Sojoodi; Dongsheng Zhang; S Ananth Karumanchi; Sahir Kalim; Sagar U Nigwekar; Ravi I Thadhani; Samir M Parikh; Raymond T Chung
Journal:  Hepatology       Date:  2019-01-04       Impact factor: 17.425

Review 8.  Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review.

Authors:  Xing-Shun Qi; Ming Bai; Zhi-Ping Yang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 9.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?

Authors:  Giovanni Tarantino; Vincenzo Citro; Paolo Conca; Antonio Riccio; Marianna Tarantino; Domenico Capone; Michele Cirillo; Roberto Lobello; Vittorio Iaccarino
Journal:  BMC Gastroenterol       Date:  2009-11-24       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.